This purpose of this proposal is to conduct a reasonable expectation of efficacy clinical trial of MMX peptide in the treatment of dogs with malignant melanoma. The protocol will determine if daily treatment with MMX leads to shrinkage of the tumor. Additional parameters to be evaluated include overall well-being and immune system modulation. This application of MMX has been granted `Minor Use' (MUMS) designation due to the low number of canine malignant melanoma cases.
This proposal is designed to test a new peptide drug for efficacy treating canine melanoma. Successful treatment would establish a new class of cancer therapeutics for this disease in the dog and would provide a much needed treatment option.
